Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blinded, Placebo-Controlled Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)

NCT00338780 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT00338780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00338780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blinded, Placebo-Controlled Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2000
Completion date
January 31, 2005
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b